These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 20720046)

  • 1. Widespread decrease of type 1 cannabinoid receptor availability in Huntington disease in vivo.
    Van Laere K; Casteels C; Dhollander I; Goffin K; Grachev I; Bormans G; Vandenberghe W
    J Nucl Med; 2010 Sep; 51(9):1413-7. PubMed ID: 20720046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early decrease of type 1 cannabinoid receptor binding and phosphodiesterase 10A activity in vivo in R6/2 Huntington mice.
    Ooms M; Rietjens R; Rangarajan JR; Vunckx K; Valdeolivas S; Maes F; Himmelreich U; Fernandez-Ruiz J; Bormans G; Van Laere K; Casteels C
    Neurobiol Aging; 2014 Dec; 35(12):2858-2869. PubMed ID: 25018107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic and type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.
    Casteels C; Vandeputte C; Rangarajan JR; Dresselaers T; Riess O; Bormans G; Maes F; Himmelreich U; Nguyen H; Van Laere K
    Exp Neurol; 2011 Jun; 229(2):440-9. PubMed ID: 21459091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioral Symptoms in Premanifest Huntington Disease Correlate with Reduced Frontal CB
    Ceccarini J; Ahmad R; Van de Vliet L; Casteels C; Vandenbulcke M; Vandenberghe W; Van Laere K
    J Nucl Med; 2019 Jan; 60(1):115-121. PubMed ID: 29934407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 1 cannabinoid receptor mapping with [18F]MK-9470 PET in the rat brain after quinolinic acid lesion: a comparison to dopamine receptors and glucose metabolism.
    Casteels C; Martinez E; Bormans G; Camon L; de Vera N; Baekelandt V; Planas AM; Van Laere K
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2354-63. PubMed ID: 20680268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
    Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
    Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-body biodistribution and radiation dosimetry of the human cannabinoid type-1 receptor ligand 18F-MK-9470 in healthy subjects.
    Van Laere K; Koole M; Sanabria Bohorquez SM; Goffin K; Guenther I; Belanger MJ; Cote J; Rothenberg P; De Lepeleire I; Grachev ID; Hargreaves RJ; Bormans G; Burns HD
    J Nucl Med; 2008 Mar; 49(3):439-45. PubMed ID: 18287275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo.
    Van Laere K; Casteels C; Lunskens S; Goffin K; Grachev ID; Bormans G; Vandenberghe W
    Neurobiol Aging; 2012 Mar; 33(3):620.e1-8. PubMed ID: 21459482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [18F]MK-9470 PET measurement of cannabinoid CB1 receptor availability in chronic cannabis users.
    Ceccarini J; Kuepper R; Kemels D; van Os J; Henquet C; Van Laere K
    Addict Biol; 2015 Mar; 20(2):357-67. PubMed ID: 24373053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.
    McCaw EA; Hu H; Gomez GT; Hebb AL; Kelly ME; Denovan-Wright EM
    Eur J Biochem; 2004 Dec; 271(23-24):4909-20. PubMed ID: 15606779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease.
    Casteels C; Lauwers E; Baitar A; Bormans G; Baekelandt V; Van Laere K
    Brain Res; 2010 Feb; 1316():153-62. PubMed ID: 20026090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study.
    Ceccarini J; Weltens N; Ly HG; Tack J; Van Oudenhove L; Van Laere K
    Transl Psychiatry; 2016 Jul; 6(7):e853. PubMed ID: 27404285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased Cannabinoid CB
    Hirvonen J; Zanotti-Fregonara P; Gorelick DA; Lyoo CH; Rallis-Frutos D; Morse C; Zoghbi SS; Pike VW; Volkow ND; Huestis MA; Innis RB
    Biol Psychiatry; 2018 Nov; 84(10):715-721. PubMed ID: 30121138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.
    Blázquez C; Chiarlone A; Sagredo O; Aguado T; Pazos MR; Resel E; Palazuelos J; Julien B; Salazar M; Börner C; Benito C; Carrasco C; Diez-Zaera M; Paoletti P; Díaz-Hernández M; Ruiz C; Sendtner M; Lucas JJ; de Yébenes JG; Marsicano G; Monory K; Lutz B; Romero J; Alberch J; Ginés S; Kraus J; Fernández-Ruiz J; Galve-Roperh I; Guzmán M
    Brain; 2011 Jan; 134(Pt 1):119-36. PubMed ID: 20929960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased cerebral cannabinoid-1 receptor availability is a stable feature of functional dyspepsia: a [F]MK-9470 PET study.
    Ly HG; Ceccarini J; Weltens N; Bormans G; Van Laere K; Tack J; Van Oudenhove L
    Psychother Psychosom; 2015; 84(3):149-58. PubMed ID: 25833408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gender-dependent increases with healthy aging of the human cerebral cannabinoid-type 1 receptor binding using [(18)F]MK-9470 PET.
    Van Laere K; Goffin K; Casteels C; Dupont P; Mortelmans L; de Hoon J; Bormans G
    Neuroimage; 2008 Feb; 39(4):1533-41. PubMed ID: 18077184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of radioligands for in vivo imaging of type 1 cannabinoid receptors (CB1) in human brain.
    Horti AG; Van Laere K
    Curr Pharm Des; 2008; 14(31):3363-83. PubMed ID: 19075713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient.
    Berding G; Schneider U; Gielow P; Buchert R; Donnerstag F; Brandau W; Knapp WH; Emrich HM; Müller-Vahl K
    Psychiatry Res; 2006 Oct; 147(2-3):249-56. PubMed ID: 16919917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The endocannabinoid-CB receptor system: Importance for development and in pediatric disease.
    Fride E
    Neuro Endocrinol Lett; 2004; 25(1-2):24-30. PubMed ID: 15159678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [18F]MK-9470, a positron emission tomography (PET) tracer for in vivo human PET brain imaging of the cannabinoid-1 receptor.
    Burns HD; Van Laere K; Sanabria-Bohórquez S; Hamill TG; Bormans G; Eng WS; Gibson R; Ryan C; Connolly B; Patel S; Krause S; Vanko A; Van Hecken A; Dupont P; De Lepeleire I; Rothenberg P; Stoch SA; Cote J; Hagmann WK; Jewell JP; Lin LS; Liu P; Goulet MT; Gottesdiener K; Wagner JA; de Hoon J; Mortelmans L; Fong TM; Hargreaves RJ
    Proc Natl Acad Sci U S A; 2007 Jun; 104(23):9800-5. PubMed ID: 17535893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.